MA-IBASIS
Today iBASIS , the leading provider of communications solutions for operators and digital players worldwide, announces the launch of its Carrier Communications Platform-as-a-Service (CPaaS) offering in partnership with Mavenir , the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects.
Since the COVID-19 pandemic began, businesses have accelerated their digital transformation programs as they’ve sought to enhance and personalize customer engagement applications with real-time and programmable communications.
Mavenir is a global CPaaS enablement partner with the power to service communications service providers (CSPs) of all sizes and provides the cloud-native platform, offering a complete set of programmable cloud communications capabilities, turnkey applications, and go-to-market assistance and training, to ensure that service providers go to market quickly.
iBASIS brings global coverage for voice, data, and messaging services, technology leadership, and a track record of quality, support and value. This creates a unique CPaaS offering that enables the addition of next-generation features into existing and new processes and software applications, in a frictionless manner, using application programming interfaces (APIs).
The iBASIS offering ranges from voice, messaging, e-commerce, and direct access to call centers across finance, healthcare, government applications, and other verticals. Businesses can now add real-time chat functionality with one-click calling via an app, and push out SMS messages to engage with their customers.
Ian Maclean , SVP, GM, Cloud Services at Mavenir, says “The integration of Mavenir's extensive CPaaS knowledge, tested platform, and best-of-breed applications with iBASIS global carrier network, voice, and messaging expertise and carrier channel reach, will unlock a market rife with opportunities for communication service providers, mobile operators and enterprise customers.”
As an independent communications specialist, iBASIS enables carriers and service providers to service their enterprise customers using their existing, trusted partners through its innovative “Bring Your Own Carrier” (BYOC) model, which is out-of-the-box, ready-to-go, and can be white-labeled.
“For too long, global telecom companies have been losing market share to new communication service providers. Through the Mavenir partnership, iBASIS is now accelerating CPaaS to telcos worldwide, enabling the digital transformation of their customer base quickly,” said Guillaume Klein , VP, Product Management at iBASIS. “The Mavenir CPaaS platform allows us to add digital transformation capabilities such as programmable SMS and voice, as well as critical market applications, such as the campaign management tool for SMS and voice calls, two-factor authentication, number masking, contact center services, and a broad portfolio of programmable communications.”
Additional Information
At Enterprise Connect (21 March – 24 March 2022), iBASIS and Mavenir will be hosting joint CPaaS solution demos. Click here to book a meeting.
* IDC: Market Analysis Perspective : Worldwide Communications Platform as a Service, 2021
About iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global , iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, Top 3 LTE IPX vendor with 700+ LTE destinations, and a leading Carrier Cloud Communications player and IoT solution provider. iBASIS provides the end-to-end Global Access for Things™ connectivity solution, delivering single source cellular IoT access (LTE, LTE-M and NB-IoT) worldwide provisioned through GSMA-standard eSIM/eUICC technology. iBASIS today serves 1,000+ customers across 21 offices worldwide. For more information, please visit iBASIS.com.
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005162/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage Network APIs Pave the Way for Freenow by Lyft to Advance Urban Mobility Innovation22.1.2026 08:00:00 CET | Press release
Freenow adopts Vonage APIs to access network capabilities, strengthening fraud prevention through faster, verified connections with drivers for millions of riders Vonage, a part of Ericsson, and Freenow by Lyft, a leading taxi and multi-mobility app in Europe, have expanded their partnership with the launch of Vonage Silent Authentication API for customers based in the U.S. Vonage Network APIs enable Freenow by Lyft to tap into real-time network data and insights, helping prevent fraud through seamless user verification, ensuring reliable, efficient, and secure interactions for its customers and drivers. Network intelligence is becoming a critical layer of defense in the transportation space as fraud threats become more sophisticated and targeted. Enterprises worldwide lost 7.7% of their annual revenue on average due to fraud over the past year, representing an estimated $534 billion in losses.¹ With scam/authorization fraud, synthetic identity fraud, and account takeover as the leadin
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe22.1.2026 07:30:00 CET | Press release
Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe. Dr. Jürgen Müller will retire after nearly 30 years of research work at Daiichi Sankyo. Under his leadership, the Translational Research Center Europe, previously called the Tissue and Cell Research Center Munich, has grown from three to 40 researchers since it was founded in 1997 and has become an internationally recognized institution that plays a strategic role in the global innovation process of Daiichi Sankyo. Dr. Veronika Rozehnal joined Daiichi Sankyo in 2009 and has held various positions at the Translational Research Center Europe in addition to spending three years at the Daiichi Sankyo R&D Center in Tokyo. Dr. Rozehnal graduated from Ernst-Moritz-Arndt University of Greifswald, Germany with a Ph.D. degree in Clinical Pharmacology. “Jürgen Müller has made significant scientific contributions that have helped Daiichi Sankyo
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 202622.1.2026 07:00:00 CET | Press release
Five presentations will showcase nizubaglustat’s therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick type C disease and GM1/GM2 gangliosidoses which are currently recruiting. Azafaros will host a satellite symposium on nizubaglustat on Day 2 of the symposium discussing the Phase 3 studies. WORLDSymposium™ 2026 takes place from February 2 to 6 in San Diego, California. Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will feature in five scientific presentations accepted at the WORLDSymposium™ 2026, the leading global conference on lysosomal diseases, taking place in San Diego, California, USA between February 2-6. The company’s conference activities include: Oral Presentations (including Poster numbers 134 and 29-C) Long-term data from a Phase II study wit
I Squared Announces Launch of Radiant Energy Solutions22.1.2026 07:00:00 CET | Press release
I Squared Capital (“I Squared”), a leading global infrastructure investment manager, announced today the launch of Radiant Energy Solutions (“Radiant”), an investment from I Squared’s Middle East infrastructure strategy, which is focused on targeting transformational, mid-market investments in the region. Reflecting I Squared’s platform-building approach of starting with a core initial investment and scaling over time to build market-leading businesses, Radiant marks the firm’s entry into the Middle East distributed renewables market, providing decarbonization solutions to commercial and industrial customers. The investment for Radiant is the acquisition of FAS Renewables and its 100% owned subsidiary Zahra Energy, a Saudi Arabia–based distributed solar company with a secured and advanced portfolio of over 100MWp of distributed solar projects with established customers and long-term contracted solar power purchase agreements. These include Cenomi Centers, an owner, operator, and develo
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio22.1.2026 07:00:00 CET | Press release
At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7 Multiple studies will reinforce the safety and efficacy of Galderma’s hyaluronic acid (HA) treatments range, including post-marketing data on Restylane® Shaype™ in shaping the chin, Restylane Lyft™ in improving jawline definition, Restylane Skinboosters™ in smoothing fine lines and wrinkles in the décolletage and Restylane Volyme™ in correcting hollowing of the temples8-11 New data on the innovative neuromodulator Relfydess™ (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow’s feet12 As a leader in injectable aesthetic innovation, Galderma will showcase its superior science and edu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom